Personal profile
Headline
ASSOCIATE CLINICAL PROFESSOR
Fingerprint
Dive into the research topics where Karen Burke is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
-
Nutraceuticals
Burke, K. E., 1 Jan 2024, Cosmeceuticals: Procedures in Cosmetic Dermatology Series, Fourth Edition. Elsevier, p. 270-282 13 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
-
Antiaging regimens
Burke, K. E., 4 Feb 2022, Cosmetic Dermatology: Products and Procedures. wiley, p. 571-586 16 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
1 Scopus citations -
Skin Cancer Induced by Pollution-Mediated ROS
Burke, K. E., 1 Jan 2022, Handbook of Oxidative Stress in Cancer: Mechanistic Aspects. Springer Nature, Vol. 1. p. 35-56 22 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
-
Environmental aging of the skin: new insights
Burke, K. E., 2020, In: Plastic and Aesthetic Research. 7, 59.Research output: Contribution to journal › Review article › peer-review
Open Access8 Scopus citations -
Dietary Lycopene Protects SKH-1 Mice Against Ultraviolet B-Induced Photocarcinogenesis
Zhou, X., Burke, K. E., Wang, Y. & Wei, H., Dec 2019, In: Journal of Drugs in Dermatology. 18, 12, p. 1244-1254 11 p.Research output: Contribution to journal › Article › peer-review
9 Scopus citations
Press/Media
-
Akebia Therapeutics drops 3.8% in Week 11 of 2026: SEC Filings, Insider Filings and Financial Highlights
23/03/26
1 item of Media coverage
Press/Media
-
Weekly: Akebia Therapeutics (AKBA: $1.41) drops 3.8% on weak volume; -5.5c [-3.8%]
23/03/26
1 item of Media coverage
Press/Media
-
Akebia Therapeutics surges 14.1% in Week 10 of 2026: SEC Filings, Insider Filings and Financial Highlights
16/03/26
1 item of Media coverage
Press/Media
-
Weekly: Akebia Therapeutics (AKBA: $1.46) surges 14% on thin volume; +18c [14.1%]
16/03/26
1 item of Media coverage
Press/Media
-
Weekly: Akebia Therapeutics (AKBA: $2.55) climbs 4.1%, 2 weeks' volume in a week; +10c [4.1%] Vol Index 1.6 [1 is avg]
10/05/25
1 item of Media coverage
Press/Media